0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Research Letter | 
Kevin R. Riggs, MD, MPH; Jodi B. Segal, MD, MPH; Eun Ji Shin, MD, PhD; et al.
JAMA. 2016;315(5):514-515. doi:10.1001/jama.2015.15278.

Original Investigation | 
Alexi A. Wright, MD, MPH; Nancy L. Keating, MD, MPH; John Z. Ayanian, MD, MPP; et al.
JAMA. 2016;315(3):284-292. doi:10.1001/jama.2015.18604.
Includes: CME, Supplemental Content

News From the Centers for Disease Control and Prevention | 
JAMA. 2016;315(2):123. doi:10.1001/jama.2015.17834.

Research Letter | 
Christine M. Veenstra, MD, MSHP; Scott E. Regenbogen, MD, MPH; Sarah T. Hawley, PhD, MPH; et al.
JAMA. 2015;314(24):2688-2690. doi:10.1001/jama.2015.12383.

Global Health | 
M. J. Friedrich
JAMA. 2015;314(23):2496. doi:10.1001/jama.2015.16382.

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2015;314(17):1789. doi:10.1001/jama.2015.14009.

Editorial | 
J. Michael McGinnis, MD, MPP
JAMA. 2015;314(16):1699-1700. doi:10.1001/jama.2015.12391.

Editorial | 
Scott A. Strong, MD; Nathaniel J. Soper, MD
JAMA. 2015;314(13):1343-1345. doi:10.1001/jama.2015.11454.

Original Investigation | 
James Fleshman, MD; Megan Branda, MS; Daniel J. Sargent, PhD; et al.
JAMA. 2015;314(13):1346-1355. doi:10.1001/jama.2015.10529.
Includes: CME, Supplemental Content

Original Investigation | 
Andrew R. L. Stevenson, MB BS, FRACS; Michael J. Solomon, MB BCh, MSc, FRCSI, FRACS; John W. Lumley, MBBS, FRACS; et al.
JAMA. 2015;314(13):1356-1363. doi:10.1001/jama.2015.12009.
Includes: Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
Biomarkers of Fluorouracil Toxicity Insight From the PETACC-8 Trial
Steven M. Offer, PhD; Robert B. Diasio, MD
JAMA Oncology
Original Investigation  | 
DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer A Secondary Analysis of the PETACC-8 Randomized Clinical Trial
Valérie Boige, MD, PhD; Marc Vincent, PhD; Philippe Alexandre, MS; et al.
JAMA Oncology
Invited Commentary  | 
Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer Requirements for Accurate Prognosis Assessment
Dirk Klingbiel, PhD; Sabine Tejpar, MD, PhD
JAMA Oncology
Original Investigation  | 
Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial
Julien Taieb, MD, PhD; Aziz Zaanan, MD, PhD; Karine Le Malicot, MS; et al.